Pricing Log in Create free account

Akebia Therapeutics, Inc. (AKBA) vs BioAge Labs, Inc. (BIOA)

Akebia Therapeutics, Inc. and BioAge Labs, Inc. are both Drug Manufacturers Specialty & Generic companies. BioAge Labs, Inc. is the larger, with a market value of $254.3M against $117.9M — 2.2× the size. Akebia Therapeutics, Inc. has the higher net margin (−22.6% vs −1,253.6%) and the higher return on invested capital (0.00% vs −21.8%). Across the 16 metrics below, Akebia Therapeutics, Inc. leads on 10 and BioAge Labs, Inc. on 6.

Valuation

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 0.60 29.58 2.08
P/B 5.84 0.73 1.79
Price to free cash flow 8.59 n/m 16.29
EV/EBITDA n/m 0.52 12.22
EV/Sales 0.05 (7.23) 2.87
Earnings yield (37.21%) (46.03%) (15.94%)
Free cash flow yield 11.64% (101.34%) 0.00%

Profitability

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
Gross margin 78.90% 100.00% 53.51%
Operating margin (15.74%) (1,401.81%) 0.00%
Net margin (22.60%) (1,253.60%) (2.45%)
Free cash flow margin 7.03% (2,997.41%) 0.00%
Return on equity (143.83%) (34.56%) (0.80%)
Return on assets (12.62%) (32.05%) (1.67%)
Return on invested capital 0.00% (21.75%) 0.00%

Growth

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (12.38%) — 5.22%
EPS growth (last fiscal year) 93.94% 66.21% 42.91%
Revenue growth, 5-year CAGR (4.33%) — 7.24%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
Debt to equity 2.47 0.00 0.04
Current ratio 1.36 15.51 2.41
Net debt to EBITDA (5.51) 3.01 1.01

Dividend

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric AKBA BIOA Drug Manufacturers Specialty & Generic median
Market cap 117.91m 254.27m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack